Risk of incident fragility fractures in patients in the fourth quartiles of cardiovascular biomarkers (CT-proAVP, CT-proET-1, MR-proADM and MR-proANP) in multivariable Cox regression model
| HR (95% CI) | ||||||
| Fracture at any site | Vertebral (n=104) | Upper (n=118) | Forearm (n=153) | Femoral (n=312) | Tibial (n=100) | |
| C-statistic (95% CI) | 0.656 (0.550 to 0.789) | 0.659 (0.497 to 0.791) | 0.641 (0.486 to 0.786) | 0.645 (0.490 to 0.780) | 0.648 (0.501 to 0.790) | 0.641 (0.484 to 0.787) |
| No biomarker in Q4 (n=4067) | Reference | Reference | Reference | Reference | Reference | Reference |
| One biomarker in Q4 (n=518) | 1.03 (0.67 to 1.10) | 0.76 (0.33 to 1.51) | 0.55 (0.13 to 1.02) | 0.75 (0.43 to 1.33) | 0.76 (0.46 to 1.23) | 1.23 (0.66 to 2.30) |
| Two biomarkers in Q4 (n=263) | 1.36 (1.05 to 1.76) | 2.16 (1.21 to 3.86) | 1.20 (0.67 to 2.16) | 1.47 (0.88 to 2.45) | 1.54 (0.98 to 2.40) | 1.01 (0.45 to 1.85) |
| Three biomarkers in Q4 (n=247) | 1.26 (0.92 to 1.64) | 2.01 (1.07 to 3.39) | 1.13 (0.63 to 2.03) | 0.78 (0.35 to 1.13) | 0.98 (0.45 to 1.44) | 0.95 (0.42 to 2.17) |
| Four biomarkers in Q4 (n=324) | 2.32 (1.86 to 2.91) | 3.16 (1.97 to 5.07) | 1.18 (0.67 to 2.08) | 0.83 (0.44 to 1.58) | 2.35 (1.64 to 3.36) | 1.21 (0.59 to 2.50) |
Adjusted for age, gender, body mass index, systolic blood pressure, heart rate, antihypertensive treatment, smoking, diabetes, prevalent fractures, history of cardio/cerebrovascular disease and physical activity. Only fracture sites with incidence over 100 cases were analysed.
Q4, fourth quartile.